In summary, the hitherto described disastrous consequences of a seemingly innocuous and highly utilized drug, Zol, in an SSc patient, which prompted these investigations, led to the discovery of a novel prothrombotic pathway involving Vγ9δ2 γδ T cells and CD14+ monocytes and a disease-specific activation of IL-4 producing Vδ1 γδ T cells. Here, CD14 is linked to systemic sclerosis.